Search results
L42 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2024 edition of ICD-10-CM L42 became effective on October 1, 2023. This is the American ICD-10-CM version of L42 - other international versions of ICD-10 L42 may differ. The following code (s) above L42 contain annotation back ...
F98.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2024 edition of ICD-10-CM F98.3 became effective on October 1, 2023. This is the American ICD-10-CM version of F98.3 - other international versions of ICD-10 F98.3 may differ. The following code (s) above F98.3 contain annotation ...
Contact with and (suspected) exposure to mold (toxic) Z77.120 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2024 edition of ICD-10-CM Z77.120 became effective on October 1, 2023.
B08.20 is a billable diagnosis code used to specify a medical diagnosis of exanthema subitum [sixth disease], unspecified. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code B08.20 is applicable for patients aged 0 through 17 years inclusive.
G24.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2024 edition of ICD-10-CM G24.9 became effective on October 1, 2023. This is the American ICD-10-CM version of G24.9 - other international versions of ICD-10 G24.9 may differ. Applicable To.
R19.8 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Oth symptoms and signs involving the dgstv sys and abdomen The 2024 edition of ICD-10-CM R19.8 became effective on October 1, 2023.
Apr 13, 2022 · ICD-10-CM code U07.1, COVID-19, may be used for discharges/date of service on or after April 1, 2020. For more information on this code, click here.The code was developed by the World Health Organization (WHO) and is intended to be sequenced first followed by the appropriate codes for associated manifestations when COVID-19 meets the definition of principal or first-listed diagnosis.
